BMS 213 (Daklinza 30 mg)
Generic Name: daclatasvir
Pill with imprint BMS 213 is Green, Five-sided and has been identified as Daklinza 30 mg. It is supplied by Bristol-Myers Squibb Company.
Daklinza is used in the treatment of hepatitis c and belongs to the drug class NS5A inhibitors. Daklinza 30 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for BMS 213
Daklinza
- Generic Name
- daclatasvir
- Imprint
- BMS 213
- Strength
- 30 mg
- Color
- Green
- Shape
- Five-sided
- Availability
- Prescription only
- Drug Class
- Ns5a inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-0213
More about Daklinza (daclatasvir)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- 10 Reviews
- Drug class: NS5A inhibitors
- FDA Alerts (1)
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.